X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AANJANEYA LIFECARE with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. DATSONS LABS vs PANACEA BIOTECH - Comparison Results

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. DATSONS LABS PANACEA BIOTECH DR. DATSONS LABS/
PANACEA BIOTECH
 
P/E (TTM) x -10.9 -19.3 - View Chart
P/BV x 0.2 2.3 7.1% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 DR. DATSONS LABS   PANACEA BIOTECH
EQUITY SHARE DATA
    DR. DATSONS LABS
Mar-14
PANACEA BIOTECH
Mar-14
DR. DATSONS LABS/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs126149 84.5%   
Low Rs3182 37.5%   
Sales per share (Unadj.) Rs133.084.1 158.1%  
Earnings per share (Unadj.) Rs0.2-18.3 -0.8%  
Cash flow per share (Unadj.) Rs6.6-6.7 -98.6%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs128.883.7 153.9%  
Shares outstanding (eoy) m31.6661.25 51.7%   
Bonus/Rights/Conversions FCCB--  
Price / Sales ratio x0.61.4 42.9%   
Avg P/E ratio x516.1-6.3 -8,180.6%  
P/CF ratio (eoy) x11.8-17.2 -68.7%  
Price / Book Value ratio x0.61.4 44.0%  
Dividend payout %00-   
Avg Mkt Cap Rs m2,4777,074 35.0%   
No. of employees `000NA2.8 0.0%   
Total wages/salary Rs m561,449 3.9%   
Avg. sales/employee Rs ThNM1,874.1-  
Avg. wages/employee Rs ThNM527.0-  
Avg. net profit/employee Rs ThNM-407.7-  
INCOME DATA
Net Sales Rs m4,2115,154 81.7%  
Other income Rs m79100 78.9%   
Total revenues Rs m4,2895,254 81.6%   
Gross profit Rs m569-766 -74.2%  
Depreciation Rs m204711 28.7%   
Interest Rs m4301,503 28.6%   
Profit before tax Rs m13-2,881 -0.4%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m-2-6 31.6%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m617 36.3%   
Profit after tax Rs m5-1,121 -0.4%  
Gross profit margin %13.5-14.9 -90.8%  
Effective tax rate %48.0-0.6 -8,235.4%   
Net profit margin %0.1-21.8 -0.5%  
BALANCE SHEET DATA
Current assets Rs m6,8523,810 179.8%   
Current liabilities Rs m6,7118,365 80.2%   
Net working cap to sales %3.3-88.4 -3.8%  
Current ratio x1.00.5 224.2%  
Inventory Days Days161156 103.3%  
Debtors Days Days31867 473.7%  
Net fixed assets Rs m3,67314,480 25.4%   
Share capital Rs m31761 516.5%   
"Free" reserves Rs m3,761903 416.5%   
Net worth Rs m4,0785,127 79.5%   
Long term debt Rs m1,6715,832 28.7%   
Total assets Rs m12,63319,433 65.0%  
Interest coverage x1.0-0.9 -112.3%   
Debt to equity ratio x0.41.1 36.0%  
Sales to assets ratio x0.30.3 125.7%   
Return on assets %3.42.0 175.3%  
Return on equity %0.1-21.9 -0.5%  
Return on capital %7.73.6 211.0%  
Exports to sales %22.924.5 93.4%   
Imports to sales %14.310.2 140.4%   
Exports (fob) Rs m9641,264 76.3%   
Imports (cif) Rs m602525 114.7%   
Fx inflow Rs m9641,539 62.6%   
Fx outflow Rs m607942 64.4%   
Net fx Rs m357597 59.8%   
CASH FLOW
From Operations Rs m1,345599 224.4%  
From Investments Rs m-2,256-438 515.1%  
From Financial Activity Rs m-1,200-303 396.5%  
Net Cashflow Rs m-2,111-141 1,493.8%  

Share Holding

Indian Promoters % 4.5 74.5 6.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 0.6 -  
FIIs % 1.4 1.3 103.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 94.1 23.6 398.7%  
Shareholders   20,807 10,259 202.8%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. DATSONS LABS With:   ALEMBIC PHARMA  DISHMAN PHARMA  J.B.CHEMICALS  ASTRAZENECA PHARMA  DIVIS LABORATORIES  

Compare DR. DATSONS LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Surges 250 Points; IT, Pharma Stocks Gain Most(12:30 pm)

After opening the day in red, share markets in India are trading on a volatile note and are presently trading above the dotted line.

Related Views on News

PANACEA BIOTECH Announces Quarterly Results (4QFY18); Net Profit Down 66.5% (Quarterly Result Update)

Jun 20, 2018 | Updated on Jun 20, 2018

For the quarter ended March 2018, PANACEA BIOTECH has posted a net profit of Rs 86 m (down 66.5% YoY). Sales on the other hand came in at Rs 2 bn (up 0.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

Hindustan Aeronautics IPO: Yet Another Play on India's Defence Sector (IPO)

Mar 14, 2018

Should you apply for the IPO of state-run military aircraft maker Hindustan Aeronautics?

Bharat Dynamics IPO: Worth Betting on Defence Manufacturing? (IPO)

Mar 12, 2018

Should you apply for the IPO of Bharat Dynamics, India's first state-owned missile manufacturer?

Apollo Micro Systems Ltd. (IPO)

Jan 9, 2018

Should you subscribe to the IPO of Apollo Micro Systems Ltd?

Khadim India Ltd. (IPO)

Oct 31, 2017

Should you subscribe to the IPO of Khadim India Ltd?

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. DATSONS LABS SHARE PRICE


May 21, 2015 (Close)

TRACK DR. DATSONS LABS

  • Track your investment in DR. DATSONS LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DR. DATSONS LABS

DR. DATSONS LABS - NOVARTIS COMPARISON

COMPARE DR. DATSONS LABS WITH

MARKET STATS